An Expanded Access Programme with Iressa for patients with Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Exclusion Criteria

• - Current eligibility (i.e., meeting the inclusion and exclusion criteria except signed informed consent) for any ZD1839 protocol available to the patient, or previous enrollment in a blinded ZD1839 protocol
• - Patients from a blinded protocol may be considered for acceptance, with AstraZeneca’s permission, only after trial completion and unblinding of all patients.
• - Patients eligible for or previously enrolled in an open-label or unblinded ZD1839 clinical trial may be considered for acceptance with AstraZeneca’s permission
• - Incomplete healing from prior oncologic or other major surgery